The board of Lotus Pharmaceutical Co., Ltd. approved to enter, jointly with Alvogen US, into an exclusive agreement with NeuroRx Inc.to develop, manufacture and commercialize NRX-101. Amount, unit price, and total monetary amount of the transaction: USD 15 million. Trading counterparty and its relationship with the Company (if the trading counterparty is a natural person and furthermore is not a related party of the Company, the name of the trading counterparty is not required to be disclosed): NeuroRx, Inc., non-related party to the Company.

Terms of delivery or payment (including payment period and monetary amount), restrictive covenants in the contract, and other important terms and conditions: Pursuant to the terms and conditions of the agreement. Any other matters that need to be specified: NeuroRx, Inc. is a wholly owned subsidiary of Nasdaq-listed company, NRx Pharmaceuticals, Inc. In addition to fixed consideration, the Company has also committed to fund the registrational studies, following successful Phase 2b/3 clinical trial and a Type B meeting with FDA. The Company, jointly with Alvogen US, will pay to NeuroRx additional bonus milestones and a royalty, both contingent on sales performance following the launch.